InduPro

Executive Summary

InduPro is a biotechnology company leveraging advanced proteomics and machine learning to discover and develop novel biologic therapeutics, including antibodies and engineered proteins. Founded in 2020 and headquartered in the United States, the company has raised $85 million to date. Its platform decodes complex disease biology by analyzing protein interactions and dynamics at an unprecedented scale, aiming to identify high-value, druggable targets and rapidly generate therapeutic candidates. Focused on oncology and immunology, InduPro represents a next-generation approach to target discovery and biologic development, with the potential to address challenging indications through its data-driven platform. The company's stage is platform development, indicating it is still in the process of advancing its technology and candidates toward the clinic.

Upcoming Catalysts (preview)

• Q2 2027Series B or C Funding Round75% success
• Q4 2026Lead Program Preclinical Data Readout60% success
• Q4 2027IND Filing for First Therapeutic Candidate40% success